Having finally got over the approval line in the US, UCB S.A. is pleased with the promising start made by Bimzelx for psoriasis and has high hopes that 2024 will see green lights in four other indications for the drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?